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Hyperphosphatemia in end-stage renal disease patients: Patho- resistance to calcitriol-induced parathyroid hormone
physiological consequences. A study of 6407 end-stage renal (PTH) inhibition.
disease (ESRD) patients has shown that hyperphosphatemia Traditionally, it was assumed that hyperphosphatemiais increasingly important as a risk for mortality. Half of the
increased PTH secretion via the induction of hypocal-patients showed serum phosphorus levels of over 6.0 mg/dl; at
cemia. However, during recent years, increasing evi-the same time, an elevated calcium 3 phosphorus product
indicated increased risk of mortality. These observations lead dence of a direct effect of P on parathyroid gland has
to questions regarding the mechanisms at work in both the emerged. It had been previously shown by several au-
observed phenomena and the way in which they affect mortal- thors that the administration of a low P diet to patientsity. To answer these questions, an understanding of the patho-
with advanced chronic renal failure (CRF) led to anphysiological consequences of hyperphosphatemia is necessary.
important decrease in serum PTH, while ionized Ca and
calcitriol levels did not increase [4, 5]. It had also been
shown that P restriction in dogs with advanced CRFHyperphosphatemia is becoming an important clinical
improved secondary HPT independently of changes inissue in end-stage renal disease (ESRD) patients. This
serum Ca and calcitriol [2]. We have observed similaris best illustrated by a recent study of 6407 hemodialysis
results in rats without changes in serum Ca, P, calcitriol,patients that reveals an increased mortality risk in pa-
or the calcemic response to PTH (abstract; J Am Soctients with hyperphosphatemia [1]. In this study, patients
Nephrol 4:704, 1993). It has also been shown that hemo-with a serum phosphorus (P) level .6.5 mg/dl had a
dialysis patients may have P-related changes in PTH27% increase in mortality. After adjusting for age at
without changes in serum Ca and calcitriol [3, 6]. TheseESRD onset, race, sex, diabetes, AIDS, neoplasm, and
results suggested an effect of a low P diet in the controlactive smoking, the mortality risk was still 27% as com-
of PTH secretion; Lopez-Hilker et al postulated that “Ppared with patients with serum P in the range of 2.5–6.5
could affect the phospholipid composition of the para-mg/dl (P , 0.001). In addition, in this large study 50%
thyroid cell membrane, Ca fluxes in the parathyroid cells,of patients had serum P higher than 6.0 mg/dl. Similarly,
and/or regulation of calcitriol receptors in the parathy-an elevated calcium (Ca) 3 P product was associated
roid cell” [2]. It has been demonstrated recently by vari-with a 34% increased mortality risk. Important questions
ous investigators that P exerts a direct stimulatory effectarise from these observations. First, how does hyperphos-
in PTH secretion and parathyroid cell proliferation, bothphatemia increase mortality in ESRD patients? Second,
in vitro and in vivo. Thus, Kilav et al [7] reported a post-what mechanisms may be operative in these observa-
transcriptional decrease in PTH mRNA levels in ratstions? In this review, we will analyze the pathophysiolog-
fed with a low P diet, and Naveh-Many et al [8], studyingical consequences of hyperphosphatemia (P↑).
rats with experimental renal failure, showed that a high
P diet increased and a low P diet decreased parathyroidWORSENING OF HYPERPARATHYROIDISM
cell proliferation. Yi et al [9] demonstrated, using North-
As shown in Fig. 1, hyperphosphatemia may lead to ern blot techniques, that a moderate P restriction de-
worsening of hyperparathyroidism (HPT), increased in- creased PTH mRNA expression in rats with mild renal
cidence of soft tissue calcifications—specifically cardiac failure. Conversely, Hernandez et al [10] have shown,
calcifications and the syndrome of calciphylaxis—and using Northern blot and in-situ hybridization techniques,
that a high P diet increased PTH mRNA expression
per cell and parathyroid cell hyperplasia in normal ratsKey words: calcification, calciphylaxis, end-stage renal disease, hyper-
parathyroidism, mortality. independently of Ca, calcitriol and modifications of the
parathyroid vitamin D receptor. In addition, Almaden 1999 by the International Society of Nephrology
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Fig. 2. Sigmoidal PTH-Ca21 relationship in five patients with various
Fig. 1. Schematic representation of the deleterious effects of hyper- levels of serum P. The closed square represents the PTH-Ca21 curve
phosphatemia. in the presence of severe hyperphosphatemia (serum P, 8.5 mg/dl). The
closed diamonds represent the PTH-Ca21 later after lowering serum P
to 7.0 mg/dl. The closed circle displays the curve days later at serum P
of 5.4 mg/dl.
et al [11] and Slatopolsky et al [12] have shown in vitro
using cultures of rat parathyroid glands that P has a
Table 1. Parathyroid gland function parameters in five dialysisdirect effect on PTH secretion. This result has been con-
patients with various levels of serum P
firmed by others using bovine parathyroid tissue slices,
Serum P1 Max PTH Min PTH Set–point Cademonstrating that tissue architecture should be intact
mg/dl pg/ml pg/ml mg/dlto observe this effect since cell-to-cell interaction is prob-
8.560.6 26556210 576695 5.1260.05ably of utmost importance [13]. It is worth emphasizing
7.060.5 21686195 450663 4.8460.06
that the role of P directly regulating parathyroid cell 5.460.4 17106175 371655 4.6060.03
growth has been confirmed by other authors [11, 12] and Abbreviations are: Max PTH, maximal PTH stimulation; Min PTH, minimum
that the effect of P on the parathyroid gland seems not PTH at maximal PTH inhibition.
to be mediated through a potential effect on vitamin D
or Ca-sensing receptors [10]. These experimental obser-
vations emphasize the relevance of clinical studies on
SOFT TISSUE CALCIFICATIONESRD patients on maintenance hemodialysis. Thus,
Yudd et al evaluated the effect of P↑ on parathyroid gland Another mechanism by which P↑ contributes to the
increased morbidity and mortality of ESRD patients mayfunction of dialysis patients with severe HPT (abstract; J
Am Soc Nephrol 8:556, 1997). Five patients with a mean be in high incidence of metastatic calcification. These
conditions occur in a variety of soft tissue. In this review,PTH of 1275 6 190 pg/ml had parathyroid gland function
studies at various levels of serum P (8.5, 7.0 and 5.4 mg/ we will focus mostly on cardiac calcifications.
Calcification of cardiac tissue has been reported indl). The studies were performed within 2–3-week period.
A 1 mEq/l dialysate Ca (low Ca) was used to induce nearly 60% of dialysis patients upon autopsy [14–16].
These deposits have been identified in the myocardium,hypocalcemia and a 4 mEq/l (high Ca) to cause hypercal-
cemia. As shown in Fig. 2, the PTH/Ca sigmoidal curve pericardium, conduction system, aortic and mitral valves,
small myocardial arteries, and the coronary arteries [17–was evaluated at various serum P levels; the sigmoidal
curve and set-point of Ca for PTH secretion shifted to- 23]. Damage to normal cardiac tissues following calcifi-
cation may lead to abnormal conduction and arrhythmia,ward the left as the P↑ was ameliorated. As it can be
appreciated in Table 1, basal maximal PTH stimulation left ventricular dysfunction, aortic and mitral stenosis,
and regurgitation, complete heart block, ischemia, con-and maximal was higher with more severe P↑. Thus, para-
thyroid gland function worsened with hyperphosphate- gestive cardiac failure, and death [17–23].
Factors that may promote cardiac calcification includemia, and it significantly related to the magnitude and
severity of P↑. Most important, control of P↑ improved elevated levels of parathyroid hormone, tissue alkalinity,
hyperphosphatemia, hypercalcemia, and particularly, angland function and resulted in lower PTH levels for any
Ca concentration. From these studies it is safe to assume elevated Ca-phosphate (Ca 3 P) product [17].
As mentioned earlier, a follow-up study was done tothat control of P↑ usually improves the HPT of ESRD
patients. ascertain the cause of death related to P↑ among these
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6407 patients [1]. A serum P level .6.5 mg/dl was noted related degeneration, or long-term arterial hypertension,
to correlate strongly with an increased risk of death may be particularly susceptible to metastatic calcification
caused by coronary artery disease (including myocardial in the milieu of elevated serum P levels and Ca 3 P
infarction and atherosclerotic heart disease) and other products [16, 25]. Thus, patients with poor long-term P
cardiac disorders. The relative risk of death from coro- control and existing cardiac damage (or a predisposition
nary artery disease was 52% higher for patients with P to cardiac complications) may be at greater risk for
levels .6.5 mg/dl than for patients with serum P # 6.5 calcific heart disease and cardiac death due to metastatic
mg/dl. Coronary artery calcification has been shown to calcification.
be a predictor of coronary artery disease [24]. These Studies designed to evaluate the role of hyperphospha-
observations are consistent with the hypothesis that poor temia in cardiac calcification have taken into account
P control results in coronary artery calcification leading only measurements that were made during the course of
to a higher risk of death in hyperphosphatemic dialysis the study; thus previous control of serum P and Ca 3 P
patients (abstract; J Am Soc Nephrol 9:325, 1998). product, which may be important to the overall risk of
Phosphorus control probably plays a central role in calcification, was not assessed. Nevertheless, most stud-
the development of cardiac calcification in ESRD patients ies on myocardial, valvular, and coronary artery calcifi-
[16]. In a recent study, hemodialysis patients (N 5 92) cation among ESRD patients have reported a strong
were found to have a much higher prevalence of cardiac association between calcification and elevated serum P
valve calcification by echocardiography than age- and and/or Ca 3 P product [16–20, 22, 23]. The few studies
gender-matched control subjects [16]. Calcification of that failed to correlate calcification with divalent ion
the mitral annulus was seen in 44.5% of dialysis patients abnormalities may have done so because long-term eval-
compared to 10% of normal subjects, and calcification of uation of serum P and Ca was not performed in these
the aortic annulus was noted in 52% of dialysis patients studies [14, 15, 26, 27] (abstract; J Am Soc Nephrol, 9:332,
compared to 4.3% of controls [16]. Dialysis patients with 1998).
mitral valve calcification had a significantly higher peak Another factor to be considered in the etiology of
Ca 3 P products (71 6 19 mg2/dl2) during the study than myocardial calcification is the Ca side of the Ca 3 P
patients without calcification [16]. Similarly, the mean product. Since the observation in the early 1980s that
Ca 3 P product over six successive months correlated aluminum-containing phosphate binders are toxic, Ca-
significantly with the presence of mitral valve calcifica-
containing binders have been used almost exclusively in
tion, as did age, number of years on dialysis, and duration
the dialysis population. Coincident with this change inof predialysis hypertension. The strongest predictors of
clinical practice has been an increasing use of oral cal-mitral valve calcification were age and the peak Ca 3 P
citriol which increases enteral Ca intake. Whether thisproduct (within six successive months), with the latter
large Ca load is an important factor in the developmentalso correlating with the severity of calcification. Similar
of cardiac calcification is unproven, but certainly is atrends for Ca 3 P and age were found for aortic valve
factor that should be evaluated.calcification [16]. These data suggest that sustained im-
Taken together, these data suggest a potential role forbalances in Ca and P metabolism facilitate the develop-
long-term imbalances in Ca and P in the developmentment of cardiac calcification in hemodialysis patients
of cardiac calcification. Whether the incidence of cardiac[16]. Of note, Ca 3 P products as low as 55 mg2/dl2, a
calcification and its related morbidity and mortality mayvalue well below the standard target of 70 mg2/dl2 in
be reduced by early and vigilant monitoring of serumdialysis patients, have been correlated with valvular cal-
Ca, P, and Ca 3 P product, in conjunction with aggressivecification in patients receiving long-term treatment with
P management, is unproven, but it is a worthy hypothesis.continuous ambulatory peritoneal dialysis [23].
The use of Ca-free (and aluminum-free) phosphate bind-Another recent report tracked cardiac calcifications
ers such as sevelamer hydrochloride (Renagelt) for thein a hemodialysis patient by conventional computed to-
management of hyperphosphatemic ESRD patients atmography [25]. Myocardial calcification was first de-
risk for calcific cardiac disease seems particularly appeal-tected in this patient by computed tomography nearly
ing since Ca overloading is avoided [28, 29]. Moreover,two years after her serum levels of Ca, P, and Ca 3 P
sevelamer hydrochloride has been associated with im-product peaked (84.5 mg2/dl2) [25]. Initial evidence of
proved lipid profiles, a consideration for patients at riskcalcification was observed during a period in which the
of coronary artery disease. The high rates of P↑ andpatient had relatively good P control (serum P 2.5–6.0
cardiac death in renal failure patients underscore themg/dl; Ca 3 P product 18–40 mg2/dl2), suggesting the
need for more research to define the role of P controlpotential role of other factors or that periods of poor P
in calcific heart disease, as well as to identify optimalcontrol may determine subsequent calcification [25].
Cardiac tissue previously damaged by infarction, age- approaches to P management.
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CALCIPHYLAXIS calciphylaxis and HPT was further supported by the early
observations that parathyroidectomy (PTx) dramaticallySelye first described a syndrome in the experimental
improved the syndrome [32]. Thus, ulcerative lesionsanimal in 1962 [30] and postulated that two steps are
which had persisted for months healed dramaticallyrequired to produce ectopic systemic calcifications. The
within weeks after PTx [32]. Later, PTx performed infirst step is a systemic sensitization induced by agents
other patients did not result in improvement of the pa-such as parathyroid hormone (PTH) vitamin D or a diet
tient and further aggravated the condition leading to ahigh in Ca and P. The second step requires that after a
high mobility and mortality [33].time interval (the “critical period”), exposure to appro-
Diffused vascular calcification were frequently notedpriate challenging agents by subcutaneous injections re-
in the early days of maintenance dialysis [34]. It wassulting in macroscopic, visible deposits of Ca salts (hy-
noted in 20% of dialysis patients with secondary HPTdroxyapatite) systemically and at the site of injection
[33]; it increased to 58% in patients with clinical evidencewithin 2–3 days. Selye named the syndrome “calciphy-
of HPT and to 75% in patients with severe overt HPTlaxis”. A few years later, a syndrome characterized by
[33]. Still, even in these early days at a time when second-peripheral ischemic tissular necrosis, small vessel calcifi-
ary HPT was common, calciphylaxis was uncommon.cations, and cutaneous ulcerations was reported in ure-
The Ca content of the skin was noted to be high in dialysismic patients; because of its resemblance to Selye’s animal
patients developing this syndrome [35]. Furthermore itmodel, it too was named calciphylaxis [31]. However, the
was noted to be higher when a dialysate Ca concentrationsyndrome described in the uremic patient only resembles
of 4.0 mEq/l was used [36]. In addition, while a highSelye’s model. Though a useful concept earlier, the anal-
dialysate Ca concentration was observed to aggravateogy with Selye’s model may not be warranted since the
soft tissue calcification, a decrease in dialysate Ca dra-term calciphylaxis has pathogenic implications that have
matically improved this syndrome in some patients [36].not been confirmed in humans. Thus, significant differ-
Furthermore, high dose of Ca carbonate inducing hyper-ences exist between Selye’s model and uremic calciphy-
calcemia was associated with this syndrome which was
laxis. The former was characterized by metastatic sys-
reversible with cessation of calcium carbonate ingestion
temic calcifications developing after significant invasive [37]. It is worth emphasizing that Ca-containing phos-
manipulations of the animal model, but vascular calcifi- phate binders are now universal, and most dialysis pa-
cations were not present. The latter occurs primarily in tients ingest large doses of elemental Ca. Gipstein et al
the presence of uremia with abnormalities in divalent reported a series of patients with calciphylaxis which
ions, i.e., high PTH, hypercalcemia, and hyperphos- was preceded by a period of hyperphosphatemia [32].
phatemia—and most importantly, vascular calcifications In some patients the control of P↑ resulted in a dramatic
were noted at the lesions. In retrospect, it appears now improvement of this syndrome. Later, other authors made
that the syndrome most analogous to Seyle’s is that of similar observations.
uremic soft tissue calcifications. Seyle’s model did not More recently, this syndrome has been noted in pa-
exhibit the histology consistently described with uremic tients with PTH levels close to normal and/or minimal
calciphylaxis, i.e., small vessel calcifications and intimal divalent ion abnormalities. With the advent of calcitriol
hypertrophy in association with paniculitis and small ves- and better control of HPT other factors have surfaced
sel thrombosis [31]. and have become more relevant in the triggering of calci-
The first description of calciphylaxis occurred in the phylaxis. As it reported by Coates et al [38] and Bleyer
late 1960s and early 1970s. Thus a syndrome character- et al [39] the presence of obesity, especially in Caucasian
ized by cutaneous eruptions usually occurring in patients females, is an important predisposing factor to develop
on dialysis or after renal transplantation [31]. The skin calciphylaxis. Supposedly, the areas rich in adipose tissue
lesions often presented as areas of painful molting resem- may be more prone to damage the small vessels and
bling livedo reticularis with superficial violaceous nod- promote calcifications before the cutaneous lesions and
ules involving the tip of the toes or fingers or occurring necrosis of the skin become clinically apparent. Others
about the ankles, thighs or buttocks. As the lesions pro- have noted an association with insulin-dependent diabe-
gress, they become hemorrhagic with ischemic “dry” ne- tes mellitus and calciphylaxis; however, no mention of
crosis. The bilateral symmetry, superficial nature of these obesity was made. Of special interest is the observation
lesions and persistence of palpable pulses distal to the that in four patients the lesions developed in areas that
necrosis were characteristic findings. As the lesions pro- had previously served as a site of insulin injection [40].
gressed cutaneous necrosis ensues as well as the develop- Local trauma such as subcutaneous injections of heparin,
ment of ischemic digital pain and in many cases gangrene or iron dextran may also be precipitating factors in the
of the digits. At the time, biopsy of the skin nodules local development of calciphylaxis [40].
showed Ca deposit within small arterial site (30–600 mm, The prognosis of patients with calciphylaxis is poor,
most dying of sepsis and ischemic events, and since weaverage 100 mm) of the vessel walls. A link between
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Fig. 3. A patient with secondary HPTH treated with intravenous calcitriol for 42 weeks. (A) Serum Ca21 and P during this period. (B) Serum
PTH. Note that although the patient developed severe hyperphosphatemia due to dietary noncompliance, and despite appropriate intravenous
calcitriol treatment and serum Ca21 in the upper limit of normal, PTH progressively increased after the fifth week.
Fig. 4. Schematic representation of the ma-
jor factors affecting a parathyroid cell in the
synthesis of PTH. Question mark (?) repre-
sents a hypothetical mechanism by which P↑
may interfere with VDR.
do not have a clear understanding of this syndrome ther- be minimized. Thus, local injections in adipose areas
apy is extremely difficult. An essential step is normaliza- where the lesions usually develop should be avoided
tion of Ca 3 P product together with control of second- whenever possible. Other potential factors in triggering
ary HPT described mostly patients with severe HPT [30]. calciphylaxis such as blood products, corticosteroids and
Later, special emphasis should be placed on both control immunosuppressants should be avoided.
of hyperphosphatemia and the use of a normal or low
dialysate Ca concentration no greater than 2.5 mEq/l.
HYPERPHOSPHATEMIA INTERFERENCEThe use of Ca containing P binders should be avoided
WITH CALCITRIOL: EFFECT ONsince the ingestion of large amount of Ca has been associ-
PTH INHIBITIONated with calciphylaxis. Alternative P binders like mag-
A common cause of failure of calcitriol therapy tonesium carbonate or Renagelt should be considered in
decrease PTH levels is the presence of P↑. First, as shownthe future.
Factors associated with triggering calciphylaxis should in Fig. 3, it was noted that patients with HPT as they
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